Medical Condition News

RSS

Nearly 60% of Ontarians with rheumatoid arthritis fail to receive needed care from specialists: Study

Nearly 60 per cent of Ontarians with rheumatoid arthritis - an autoimmune disease that causes chronic inflammation of the joints - were not seen by a specialist within a one year period to treat the debilitating disease, according to a new study. Even more concerning is that women of child-bearing age are less likely to see a specialist than women 45 or older, say researchers from St. Michael's Hospital, the Institute for Clinical and Evaluative Sciences, and Women's College Hospital

7 Jul 2010

Combination of Biothera's Imprime PGG and Erbitux doubles response rate in colorectal cancer patients

The combination of Biothera's experimental drug Imprime PGG® and Erbitux® (cetuximab) doubled the historical overall response rate and the time to progression of second- and third-line metastatic colorectal cancer patients treated with Erbitux monotherapy. The data was released last weekend at the 13th World Congress on Gastrointestinal Cancer at the European Society for Medical Oncology (ESMO).

7 Jul 2010

Capstone Therapeutics to continue AZX100 Phase 2a trial in dermal scarring to planned 12-month endpoints

Capstone Therapeutics announced today it has completed a limited analysis of a subset of data from its ongoing AZX100 Phase 2a clinical trial in trocar site scarring following arthroscopic shoulder surgery. Based on this analysis, the clinical trial will continue to its planned 12-month endpoints.

7 Jul 2010

ASPREE study aims to assess health benefits of aspirin

In an effort to extend the length of a disability-free life for older adults, researchers from Rush University Medical Center are partnering with colleagues from across the U.S. and Australia in the largest international trial ever sponsored by the National Institute on Aging.

7 Jul 2010

New Center for Image-Guided Intervention opened at MSKCC

Image-guided interventions are revolutionizing cancer diagnosis and treatment. MSKCC's new Center for Image-Guided Intervention (CIGI), which opened in June, offers cancer patients the most advanced, minimally invasive diagnostic and treatment options in a unique multidisciplinary setting designed to foster rapid innovations in cancer care.

7 Jul 2010

European Commission approves new indication for ORENCIA in combination with MTX for RA

Bristol-Myers Squibb Company has today announced that on 1 July 2010 the European Commission approved a new indication for ORENCIA® (abatacept), in combination with methotrexate (MTX), for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including MTX or a TNF-alpha inhibitor.

7 Jul 2010

Study: High concentrations of cocoa flavanols decrease blood pressure

A new study by UCSF cardiologists and researchers found that high concentrations of cocoa flavanols decrease blood pressure, improve the health of blood vessels and increase the number of circulating blood-vessel-forming cells in patients with heart disease. The findings indicate that foods rich in flavanols - such as cocoa products, tea, wine, and various fruits and vegetables - have a cardio-protective benefit for heart disease patients.

7 Jul 2010

Extended treatment with blood thinner benefits patients immobilized by acute medical illness: Study

A treatment plan used to prevent potentially dangerous blood clots in recovering surgical patients can also benefit some patients immobilized by acute medical illness, doctors have found in a multi-institutional study.

7 Jul 2010

New research shows cellular changes in fat tissue lead to type 2 diabetes

Cellular changes in fat tissue-not the immune system-lead to the "hyperinflammation" characteristic of obesity-related glucose intolerance and type 2 diabetes, according to new research from the University of Cincinnati.

7 Jul 2010

Cedars-Sinai Heart Institute awarded grant to develop new system to predict sudden cardiac arrest

The Cedars-Sinai Heart Institute has been awarded a $1.66 million, four-year grant from the National Heart, Lung and Blood Institute of the National Institutes of Health to develop a measurement system that could help doctors predict which patients could be struck by sudden cardiac arrest, a heart rhythm disturbance that causes instant death in more than 95 percent of cases.

7 Jul 2010

Polyethylene glycol "works a bit better" than lactulose for chronic constipation: Study

When ordinary over-the-counter laxatives fail to work, doctors turn to other medications to treat people with constipation. Now, a new review of existing research finds that one common drug treatment is better than another is at helping patients who are desperate to get things moving.

7 Jul 2010

Multicolor quantum dots can distinguish Reed-Sternberg cells, article shows

The tunable fluorescent nanoparticles known as quantum dots make ideal tools for distinguishing and identifying rare cancer cells in tissue biopsies, Emory and Georgia Tech scientists have demonstrated.

7 Jul 2010

MicroRNAs accurately identify four histological types of renal tumors: Study

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostics, announces that a peer-reviewed article entitled "Accurate Molecular Classification of Renal Tumors Using MicroRNA Expression" has been published in the online version of The Journal of Molecular Diagnostics.

7 Jul 2010

Retin-A Micro Pump combines tretinoin for treating acne: Study

From the minute they wake until the minute they sleep, today's teenagers have busy, demanding schedules. Life may be hectic, but an acne care routine doesn't have to get in the way, according to a new study published in the July 2010 issue of Journal of Drugs in Dermatology.

7 Jul 2010

Researchers show unexpected, physiological effects of water

Name a drink that can make you more alert for late-night studying, prevent you from fainting after giving blood, and even promote a teensy bit of weight loss. Chances are you didn't say water. But that's the right answer.

7 Jul 2010

Aastrom to pursue Phase 3 CLI clinical program through FDA SPA process

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that the company will pursue a Phase 3 clinical program for its autologous cell therapy for the treatment of critical limb ischemia (CLI) through the U.S. Food and Drug Administration's special protocol assessment (SPA) process. Aastrom is currently completing a Phase 2b clinical trial of its cell therapy in patients with CLI and recently met with FDA officials to discuss plans for the Phase 3 program.

7 Jul 2010

Anxiety can cause individuals become more idealistic in religious belief, researchers find

Anxiety and uncertainty can cause us to become more idealistic and more radical in our religious beliefs, according to new findings by York University researchers, published in this month's issue of the Journal of Personality and Social Psychology.

7 Jul 2010

Debiopharm's achievement of Phase I milestone in Debio 0932 trial triggers $3M milestone payment to Curis

Curis, Inc. announced today that its licensee Debiopharm S.A. has treated the fifth patient in its ongoing Phase I clinical trial for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of the August 2009 license agreement between Curis and Debiopharm, Curis will receive a $3 million milestone payment from Debiopharm for the achievement of this development objective.

7 Jul 2010

Initial Phase II study results of ofatumumab in patients with RRMS announced

Genmab A/S announced today positive interim results from an ofatumumab Phase II safety and pharmacokinetics study in patients with relapsing-remitting multiple sclerosis.

7 Jul 2010

FDA grants Fougera first generic approval for Adapalene Cream 0.1%

E. Fougera & Co., a leading specialty pharmaceutical manufacturer, announced it has received first generic approval from the FDA for Adapalene Cream 0.1% (Rx). Fougera's Adapalene Cream 0.1% is rated AB, generically equivalent to Differin® by Galderma Pharmaceuticals. According to industry data, U.S. sales of the brand named product in 2009 exceeded $55 million. This approval also marks the fourth product approval that the FDA has granted to Fougera this year.

7 Jul 2010

Medical Condition News

Nearly 60% of Ontarians with rheumatoid arthritis fail to receive needed care from specialists: Study

Combination of Biothera's Imprime PGG and Erbitux doubles response rate in colorectal cancer patients

Capstone Therapeutics to continue AZX100 Phase 2a trial in dermal scarring to planned 12-month endpoints

ASPREE study aims to assess health benefits of aspirin

New Center for Image-Guided Intervention opened at MSKCC

European Commission approves new indication for ORENCIA in combination with MTX for RA

Study: High concentrations of cocoa flavanols decrease blood pressure

Extended treatment with blood thinner benefits patients immobilized by acute medical illness: Study

New research shows cellular changes in fat tissue lead to type 2 diabetes

Cedars-Sinai Heart Institute awarded grant to develop new system to predict sudden cardiac arrest

Polyethylene glycol "works a bit better" than lactulose for chronic constipation: Study

Multicolor quantum dots can distinguish Reed-Sternberg cells, article shows

MicroRNAs accurately identify four histological types of renal tumors: Study

Retin-A Micro Pump combines tretinoin for treating acne: Study

Researchers show unexpected, physiological effects of water

Aastrom to pursue Phase 3 CLI clinical program through FDA SPA process

Anxiety can cause individuals become more idealistic in religious belief, researchers find

Debiopharm's achievement of Phase I milestone in Debio 0932 trial triggers $3M milestone payment to Curis

Initial Phase II study results of ofatumumab in patients with RRMS announced

FDA grants Fougera first generic approval for Adapalene Cream 0.1%

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News